Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn's Disease

被引:48
|
作者
Kotze, Paulo Gustavo [1 ]
Saab, Mansur Paulo [1 ]
Saab, Barbara [1 ]
da Silva Kotze, Lorete Maria [1 ]
Olandoski, Marcia [2 ]
Pinheiro, Lilian Vital [3 ]
Real Martinez, Carlos Augusto [3 ]
Setsuko Ayrizono, Maria de Lourdes [3 ]
Magro, Daniela de Oliveira [3 ]
Rodrigues Coy, Claudio Saddy [3 ]
机构
[1] Catholic Univ Parana, Colorectal Surg Unit, Cajuru Univ Hosp, Rua Bruno Filgueira 369 Cj,1205, BR-80240220 Curitiba, Parana, Brazil
[2] Catholic Univ Parana, Dept Biostat, Rua Imaculada Conceicao 1155, BR-80215901 Curitiba, Parana, Brazil
[3] Campinas State Univ UNICAMP, Colorectal Surg Unit, Rua Tessalia Vieira Camargo 126, BR-13083887 Campinas, SP, Brazil
关键词
Crohn's disease; Postoperative complications; Tumor necrosis factor alpha; Biological products; INFLAMMATORY-BOWEL-DISEASE; ANTI-TNF; FACTOR THERAPY; ANASTOMOTIC COMPLICATIONS; ABDOMINAL-SURGERY; PREOPERATIVE USE; INFLIXIMAB; METAANALYSIS; OUTCOMES; AGENTS;
D O I
10.1007/s10620-016-4400-2
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The real impact of anti-tumor necrosis alpha (TNF) therapy in postoperative complications after intestinal resections in Crohn's disease (CD) still needs to be determined. To compare the postoperative complication rates after elective intestinal resections in CD patients, with or without previous exposure to anti-TNF therapy. This was a retrospective and observational study, with elective intestinal resections for CD (emergency procedures were excluded). Patients were allocated in two groups according to preoperative anti-TNF status. Surgical and medical complications were analyzed and subsequently compared between the groups. A total of 123 patients were included (71 with and 52 without preoperative anti-TNF). The groups were considered homogeneous, except for perianal CD, previous azathioprine, and stomas. There was no significant difference between the groups regarding overall surgical complications (32.69% in anti-TNF- vs. 39.44% in anti-TNF+ patients, p = 0.457) or overall medical complications (21.15 vs. 21.13%, respectively, p = 1.000). In univariate analysis, previous steroids, perianal CD, and stomas were considered risk factors for surgical complications, and previous steroids and hypoalbuminemia for medical complications. In multivariate analysis, previous steroids were associated with higher rates of surgical and medical complications, while hypoalbuminemia was associated with higher medical complication rates. There was no influence of the previous use of anti-TNF agents in postoperative surgical and medical complication rates in elective intestinal resections for CD. Previous steroids and hypoalbuminemia were associated with higher complication rates. This was the first case series of the literature describing outcomes in exclusively elective operations.
引用
收藏
页码:456 / 464
页数:9
相关论文
共 50 条
  • [31] Anti-Tumor Necrosis Factor-Alpha (TNF-alpha) Treatment Strategies in Crohn's Disease
    Reimund, Jean-Marie
    Ratajczyk, Julia
    Sola, Brigitte
    Justum, Anne-Marie
    Muller, Christian D.
    RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2007, 1 (01) : 21 - 34
  • [32] Mechanisms of Action of Anti-tumor Necrosis Factor a Agents in Crohn's Disease
    Peake, Simon T. C.
    Bernardo, David
    Mann, Elizabeth R.
    Al-Hassi, Hafid O.
    Knight, Stella C.
    Hart, Ailsa L.
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (07) : 1546 - 1555
  • [33] Antibodies to tumor necrosis factor-α in the treatment of Crohn's disease
    Brown, SJ
    Abreu, MT
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2005, 8 (02) : 160 - 168
  • [34] Use of the tumor necrosis factor-blockers for Crohn's disease
    Alan BR Thomson
    Milli Gupta
    Hugh J Freeman
    World Journal of Gastroenterology, 2012, 18 (35) : 4823 - 4854
  • [35] The Influence of Preoperative Medications on Postoperative Complications in Patients After Intestinal Surgery for Crohn's Disease
    Yu, Chang Sik
    Jung, Sung Woo
    Lee, Jong Lyul
    Lim, Seok-Byung
    Park, In Ja
    Yoon, Yong Sik
    Kim, Chan Wook
    Yang, Suk-Kyun
    Ye, Byong Duk
    Park, Sang Hyoung
    Han, Minkyu
    Kim, Jin Cheon
    INFLAMMATORY BOWEL DISEASES, 2019, 25 (09) : 1559 - 1568
  • [36] Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: Results of a systematic review
    Fidder, Herma H.
    Singendonk, Maartje M. J.
    van der Have, Mike
    Oldenburg, Bas
    van Oijen, Martijn G. H.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (27) : 4344 - 4350
  • [37] Moxibustion Inhibits Apoptosis and Tumor Necrosis Factor-Alpha/Tumor Necrosis Factor Receptor 1 in the Colonic Epithelium of Crohn’s Disease Model Rats
    Chun-Hui Bao
    Lu-Yi Wu
    Huan-Gan Wu
    Yin Shi
    Hui-Rong Liu
    Rong Zhang
    Li-Qing Yu
    Jin-Hai Wang
    Digestive Diseases and Sciences, 2012, 57 : 2286 - 2295
  • [38] Joint Detection of Serum Vitamin D, Body Mass Index, and Tumor Necrosis Factor Alpha for the Diagnosis of Crohn's Disease
    Zheng, Ying
    Li, Jing-hong
    Liao, Shan-ying
    Fu, Yi-ming
    Zhang, Yan-jun
    Lin, Jun-long
    Chen, Xin-bin
    Sha, Wei-hong
    Dai, Shi-xue
    Ma, Wen-jun
    CURRENT MEDICAL SCIENCE, 2023, 43 (03) : 496 - 504
  • [39] Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease
    Zaccagna, A
    Bertone, A
    Puiatti, P
    Picciotto, F
    Sprujevnik, T
    Santucci, R
    Rossini, FP
    EUROPEAN JOURNAL OF DERMATOLOGY, 2003, 13 (03) : 258 - 260
  • [40] PLASMA HISTAMINE AND TUMOUR NECROSIS FACTOR-ALPHA LEVELS IN CROHN'S DISEASE AND ULCERATIVE COLITIS AT VARIOUS STAGES OF DISEASE
    Hagel, A. F.
    De Rossi, T.
    Konturek, P. C.
    Albrecht, H.
    Walker, S.
    Hahn, E. G.
    Raithel, M.
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2015, 66 (04): : 549 - 556